Phage therapy science – still weak

If you’ve read very much of this blog, you know that my opinion of phage science in general is not very high. I haven’t been especially nice about expressing this opinion either, tossing out epithets like “weak”, “porcine” and “innumerate”. The latter, I suspect, riled up Stephanie Strathdee, one of the co-authors of the paper Read More …

Right to Rob – the race begins

I recently wrote that the Right-to-Try legislation would inevitably become Right-to-Rob. Although Merck and other pharma incumbents (weakly) opposed the law, it wouldn’t be long until small cash-strapped companies began exploiting it to improve their finances. That day has arrived. Bloomberg reports that BrainStorm Cell Therapeutics will begin selling its investigational ALS treatment to patients. Read More …

How to reduce rising drug costs in the US

The first and most fundamental change is to give up the idea that free market economics are always and everywhere optimal. This faith – and it is a faith, with its own Holy Ghost (the Invisible Hand) – has cleaned out the wallets of Americans with an efficiency that would excite the envy of a TV preacher. Those Read More …

Would Theranos still be operating if not for John Carreyou?

I’m not much of a believer in “Great Man” theories, especially in science. There are a lot of smart, hardworking scientists out there. Someone has to be first to make a discovery, but they rarely finish the race more than a step or two ahead of their competitors. If not Newton, then Liebniz. If not Read More …

Why plant-derived antibiotics are not a thing

We’ve been using plants as medicines for a long time. Longer than history — hollyhock has been found in the graves of Neanderthals, and yarrow and chamomile have been found on their teeth [1]. Longer indeed than humanity itself — many animals self-medicate, including chimpanzees, monkeys, baboons and lemurs [2]. A long time. Plants are full Read More …